Glaukos Corporation (NYSE:GKOS) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Glaukos Corporation (the Company) intends to present the materials attached as Exhibit 99.1 to this Current Report on Form 8-K (the Investor Presentation) from time to time in presentations to investors and other stakeholders. The Investor Presentation will also be available on the investor page of the Companys website at http://investors.glaukos.com.
The information contained in this Item 7.01 (excluding Exhibit 99.1) shall not be deemed filed for purposes of the Exchange Act, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing of the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
GLAUKOS Corp Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 Exhibit 99.11 © 2019 Glaukos Corporation 1 March 20192 © 2019 Glaukos Corporation All statements other than statements of historical facts included in this presentation that address activities,…
To view the full exhibit click
About Glaukos Corporation (NYSE:GKOS)
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.